Updated Harmoni-6 data is raising questions for Akeso and Summit’s ivonescimab, with updated analysis showing that the PD-1/VEGF bispecific antibody’s progression-free survival benefit narrowed with longer follow-up. The question is centered on whether the continued dataset still supports a durable clinical effect for the intended populations. For biotech decision-makers, the update stresses how quickly efficacy claims can shift as follow-up matures—particularly for bispecifics that may show time-dependent benefits. It also affects how investors and trial designers interpret endpoint robustness for later-stage programs and potential regulatory discussions. Companies now have to weigh whether to adjust comparators, endpoint strategy, or subgroup emphasis as long-term curves come into view.